The understanding of molecular mechanisms underlying the EZH2-miR-29b/miR-30d-LOXL4 axis affords a novel insight in diagnosis, prognosis, and molecularly targeted therapy of breast cancer and may provide a novel therapeutic approach for breast cancer treatment in the clinic. This evidence concerns the gene LOXL4 and breast cancer.